



10745 Westside Way, Suite 200

Alpharetta, GA 30009

Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtvision.com

www.vtvisioninvestors.com (for investors)

ASX Announcement

Visioneering Technologies, Inc. Reports Q2 2018 Results

Atlanta, Georgia, USA 25 July 2018 (26 July 2018 AT): Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue® Multifocal 1 Day (NaturalVue MF) Contact Lenses will release its Appendix 4C – Quarterly Cash Flow for the period ended 30 June 2018 (2Q18), on Friday 27th July AEST.

Investor Conference Call

Investors are invited to join a conference call on Friday, 27 July at 10.30am AEST (Thursday, 26 July 9.30pm US EDT) hosted by Visioneering's CEO, Stephen Snowdy.

To pre-register for the call please use this link:

<https://services.choruscall.com.au/diamondpass/vtvision-723615-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call. Alternatively you can dial in using the details below at the scheduled call start time.

Conference ID: 723 615

Participant Dial In Numbers

Australia Toll Free:	1 800 558 698
Alternate Australia Toll Free:	1 800 809 971
Australia Local:	02 9007 3187
Canada:	1855 8811 339
Japan:	0053 116 1281
New Zealand Toll Free:	0800 453 055
United Kingdom:	0800 051 8245
United States:	(855) 881 1339
US Local (New York):	(914) 202 3258
US Local (Los Angeles):	(909) 235 4020

For more information, please contact:

<i>Company</i>	<i>Investor and media relations</i>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Kyahn Williamson or Lauren Nowak WE Buchan Tel: +61 (3) 9866 4722 Email: vti@we-buchan.com

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue® Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics® technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. VTI also sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.